Abbott Laboratories (NYSE:ABT) had its target price lifted by Stifel Nicolaus from $58.00 to $63.00 in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage currently has a buy rating on the healthcare product maker’s stock.

Several other analysts have also commented on the company. Royal Bank Of Canada lifted their price objective on Abbott Laboratories from $55.00 to $60.00 and gave the stock an outperform rating in a report on Thursday. Jefferies Group LLC reaffirmed a buy rating and issued a $65.00 price objective on shares of Abbott Laboratories in a report on Thursday. Zacks Investment Research raised Abbott Laboratories from a hold rating to a buy rating and set a $61.00 price objective for the company in a report on Monday, October 16th. J P Morgan Chase & Co began coverage on Abbott Laboratories in a report on Friday, October 6th. They issued a neutral rating and a $60.00 price objective for the company. Finally, Bank of America Corporation reaffirmed a buy rating and issued a $60.00 price objective (up previously from $56.00) on shares of Abbott Laboratories in a report on Wednesday, October 4th. Seven equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $56.81.

Abbott Laboratories (ABT) opened at 56.32 on Thursday. Abbott Laboratories has a 12 month low of $37.38 and a 12 month high of $56.60. The stock’s 50 day moving average price is $53.27 and its 200-day moving average price is $48.51. The stock has a market cap of $97.85 billion, a PE ratio of 78.88 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. Abbott Laboratories had a return on equity of 14.50% and a net margin of 8.37%. The company had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. During the same quarter in the previous year, the company posted $0.59 earnings per share. Abbott Laboratories’s revenue was up 28.8% compared to the same quarter last year. Analysts anticipate that Abbott Laboratories will post $2.50 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/stifel-nicolaus-boosts-abbott-laboratories-abt-price-target-to-63-00/1647058.html.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be given a $0.265 dividend. The ex-dividend date is Thursday, October 12th. This represents a $1.06 annualized dividend and a dividend yield of 1.88%. Abbott Laboratories’s payout ratio is 83.47%.

In other news, insider Brian J. Blaser sold 15,000 shares of the business’s stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $50.00, for a total value of $750,000.00. Following the transaction, the insider now directly owns 143,154 shares in the company, valued at $7,157,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Hubert L. Allen sold 4,600 shares of the business’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $50.79, for a total value of $233,634.00. Following the completion of the transaction, the insider now owns 105,479 shares in the company, valued at $5,357,278.41. The disclosure for this sale can be found here. Insiders sold 333,310 shares of company stock worth $16,857,255 over the last 90 days. Company insiders own 0.76% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Tributary Capital Management LLC purchased a new position in shares of Abbott Laboratories in the third quarter valued at about $106,000. Heritage Trust Co lifted its position in shares of Abbott Laboratories by 10.1% in the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after acquiring an additional 200 shares in the last quarter. Winfield Associates Inc. lifted its position in shares of Abbott Laboratories by 3.9% in the second quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock valued at $116,000 after acquiring an additional 89 shares in the last quarter. Thompson Davis & CO. Inc. lifted its position in shares of Abbott Laboratories by 17.7% in the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after acquiring an additional 370 shares in the last quarter. Finally, V Wealth Management LLC purchased a new position in shares of Abbott Laboratories in the second quarter valued at about $127,000. Institutional investors and hedge funds own 71.45% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Analyst Recommendations for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.